Form 4: Ventyx Biosciences Chief Scientific Officer Acquires Stock Options

John Nuss, Chief Scientific Officer of Ventyx Biosciences, acquired stock options for 415,104 shares of common stock on January 2, 2025.

Summary

• On January 2, 2025, John Nuss, the Chief Scientific Officer of Ventyx Biosciences, acquired stock options.
• These options grant him the right to buy 245,000 shares at $2.14 per share and 170,104 shares at $2.14 per share.
• The options vest monthly, with 1/48th of the total shares vesting each month following the Vesting Commencement Date of January 2, 2025, contingent upon continued service.
• The options expire on January 2, 2035.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock option grants, and does not inherently convey positive or negative sentiment. It's a neutral disclosure of information.

Future Outlook

The document does not contain any specific forward-looking statements or guidance regarding the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in the biotechnology industry where equity compensation is frequently used to incentivize key personnel. It provides transparency into the holdings and transactions of company executives.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies like Ventyx Biosciences.
• Companies such as Amgen, Gilead Sciences, and Biogen also utilize stock options to align executive incentives with shareholder value.
• The vesting schedule of 1/48th per month is a typical vesting arrangement.
• The exercise price of $2.14 is a key factor in determining the value of the options to the executive.

Stakeholder Impact

• The acquisition of stock options by the Chief Scientific Officer aligns his interests with those of shareholders, incentivizing him to contribute to the company's long-term success.

Key Dates